Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage

This publication has 11 references indexed in Scilit:

• Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
  British Journal of Cancer, 1999
• The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53
  Proceedings of the National Academy of Sciences, 1999
• Frequent Co‐Alterations of TP53, p16/CDKN2A, p14^ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.
  Brain Pathology, 1999
• Topotecan treatment of adults with primary malignant glioma
  Cancer, 1999
• Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses
  International Journal of Cancer, 1998
• Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
  British Journal of Cancer, 1998
• Synergy of CD95 ligand and teniposide: No role of cleavable complex formation and enhanced CD95 expression
  European Journal of Pharmacology, 1998
• Current perspectives on camptothecins in cancer treatment
  British Journal of Cancer, 1996
• Phase II study of topotecan in patients with recurrent malignant glioma
  Annals of Oncology, 1996
• Modulation of DNA Topoisomerase I Activity by p53
  Biochemistry, 1996